Market Spotlight: Ischemic Stroke
Market Spotlight: Ischemic Stroke
$1,318.00
This Market Spotlight report covers the Ischemic Stroke market, comprising key marketed and pipeline drugs, clinical trials, recent events and analyst opinion, upcoming and regulatory events, probability of success, licensing and asset acquisition deals and a 10-year disease prevalence forecast, as well as presenting drug-specific revenue forecasts.
Publisher: Datamonitor Healthcare
- Description
- Contents
This Market Spotlight report covers the Ischemic Stroke market, comprising key marketed and pipeline drugs, clinical trials, recent events and analyst opinion, upcoming events, probability of success, licensing and asset acquisition deals, and a 10-year disease prevalence forecast, as well as presenting drug-specific revenue forecasts.
Key Takeaways
- Datamonitor Healthcare estimates that in 2021, there were approximately 82.3 million prevalent cases of ischemic stroke worldwide, and forecasts that number to increase to 87.5 million prevalent cases by 2029.
- The approved drugs in the ischemic stroke space focus on a wide variety of targets. Most approved drugs are administered orally, with the remainder being available in intravenous, subcutaneous, and sublingual/oral transmucosal formulations.
- The majority of industry-sponsored drugs in active clinical development for ischemic stroke are in Phase II. Therapies in active clinical development for ischemic stroke focus on a wide variety of targets and include small molecules, peptides, and cell-based therapies.
- High-impact upcoming events for drugs in the ischemic stroke space comprise topline Phase II trial results for Milvexian, topline Phase III trial results for Cirara, and an expected PDUFA date for HPC-Cord Blood.
- The overall likelihood of approval of a Phase I ischemic stroke asset is 0.9%, and the average probability a drug advances from Phase III is 11.1%. Drugs, on average, take 13.1 years from Phase I to approval, compared to 10.2 years in the overall neurology space.
- The distribution of clinical trials across Phase I–IV indicates that the majority of trials for stroke have been in the early and midphases of development, with 70% of trials in Phase I–II, and 30% in Phase III–IV.
- The US has a substantial lead in the number of stroke clinical trials globally. Germany leads the major European markets, while China has the top spot in Asia.
- Clinical trial activity in the stroke space is dominated by completed trials. Mitsubishi Tanabe has the highest number of completed clinical trials for stroke, with 15 trials.
- Boehringer Ingelheim and Roche lead industry sponsors with the highest overall number of clinical trials for stroke.
CONTENTS
6 OVERVIEW
7 KEY TAKEAWAYS
8 DISEASE BACKGROUND
8 Disease definition
8 Symptoms
9 Risk factors
9 Diagnosis
11 TREATMENT
11 Acute treatment of ischemic stroke
11 Long-term treatments
11 Palliative care
12 EPIDEMIOLOGY
16 MARKETED DRUGS
19 PIPELINE DRUGS
25 RECENT EVENTS AND ANALYST OPINION
25 Asundexian for Ischemic Stroke (August 29, 2022)
26 Milvexian for Ischemic Stroke (August 28 2022)
28 LT3001 for Ischemic Stroke (August 3, 2021)
29 TMS-007 for Ischemic Stroke (May 12, 2021)
32 KEY UPCOMING EVENTS
33 PROBABILITY OF SUCCESS
34 LICENSING AND ASSET ACQUISITION DEALS
34 Simcere In-Licenses Avilex Pharma CNS Drug Candidate
35 REVENUE OPPORTUNITY
36 CLINICAL TRIAL LANDSCAPE
37 Sponsors by status
38 Sponsors by phase
39 Recent events
42 BIBLIOGRAPHY
43 APPENDIX
LIST OF FIGURES
15 Figure 1: Trends in prevalent cases of ischemic stroke, 2021–30
19 Figure 2: Overview of pipeline drugs for ischemic stroke in the US
19 Figure 3: Pipeline drugs for ischemic stroke, by company
20 Figure 4: Pipeline drugs for ischemic stroke, by drug type
20 Figure 5: Pipeline drugs for ischemic stroke, by classification
26 Figure 6: Asundexian for Ischemic Stroke (August 29, 2022): Phase II – PACIFIC-STROKE
29 Figure 7: LT3001 for Ischemic Stroke (August 3, 2021): Phase IIa – 201
31 Figure 8: TMS-007 for Ischemic Stroke (May 12, 2021): Phase IIa – Single IV Administration (JP)
32 Figure 9: Key upcoming events in ischemic stroke
33 Figure 10: Probability of success in the ischemic stroke pipeline
36 Figure 11: Clinical trials in stroke
36 Figure 12: Top 10 drugs for clinical trials in stroke
37 Figure 13: Top 10 companies for clinical trials in stroke
37 Figure 14: Trial locations in stroke
38 Figure 15: Stroke trials status
39 Figure 16: Stroke trials sponsors, by phase
LIST OF TABLES
13 Table 1: Prevalent cases of ischemic stroke, 2021–30
17 Table 2: Marketed drugs for ischemic stroke
21 Table 3: Pipeline drugs for ischemic stroke in the US
25 Table 4: Asundexian for Ischemic Stroke (August 29, 2022)
27 Table 5: Milvexian for Ischemic Stroke (August 28 2022)
28 Table 6: LT3001 for Ischemic Stroke (August 3, 2021)
30 Table 7: TMS-007 for Ischemic Stroke (May 12, 2021)
35 Table 8: Historical global sales, by drug ($m), 2017–21
35 Table 9: Forecasted global sales, by drug ($m), 2022–26
© Pharma Intelligence UK Ltd. This document is a licensed product and is not to be reproduced or redistributed
Do you have a subscription to Datamonitor Healthcare, Biomedtracker or Meddevicetracker? You may already have access to these reports, contact your account manager or email pharma@informabi.com for further help or assistance.
Disease Analysis: Depression 
Sign up to the